You're at the End of the Runway and the Financing Window is Closed

ABFO, The Association of Bioscience Financial Officers

May 2008

TO: ABFO MEMBER REPRESENTATIVES, COLLEAGUES AND GUESTS

FROM: YOUR ABFO NORCAL BOARD OF DIRECTORS

**RSVP NOW FOR OUR NEXT ABFO DINNER EVENT**

You're at the End of the Runway but the Financing Window is Closed -

The current economic climate is making raising money in the equity markets a risky proposition to on which to bet your company's financial future. There is an election still six months away and with the summer doldrums almost here, making for even more uncertainty.

If you think you are going to need to raise money in the near to medium term, it makes sense to get better acquainted with all of the financing vehicles that potentially are available to you. The evening program is designed for both the public and the private company. We have lined up two industry experts to walk you through the mechanics of the financing vehicles they provide and an ABFO CFO to talk about several others that he has also successfully employed.

Our Featured Speakers to be:

Kathleen Conte, Managing Director
Hercules Technology Growth Capital

Jim Scopa, Managing Director
MPM Capital

Dan Spiegelman, Sr. Vice President,
Chief Financial Officer, CV Therapeutics, Inc.

		Kathy Conte is Managing Director of Life Sciences, Hercules Technology Growth Capital, a finance company providing venture debt and equity to venture capital and private equity backed technology and life science companies. They offer growth capital to companies at all stages of development and specialize in venture debt in the forms of senior and subordinated working capital loans, senior revolving loans and bridge loans, venture leasing and select direct equity capital. Kathy's resumé includes a career in commercial lending and private placements
Jim Scopa is Managing Director on the BioVentures Team of MPM Capital. MPM is the world's largest dedicated investor in life sciences. In addition to its venture capital funds, MPM Capital invests in the public markets through its hedge fund. MPM focuses primarily on biotechnology and biopharmaceuticals as well as medical devices. Jim also brings an extensive background in healthcare investment banking from Thomas Weisel Partners and Deutsche Banc Alex Brown.
	Dan Spiegelman is Senior Vice President and Chief Financial Officer of CV Therapeutics, where he has creatively led the financing effort for a decade. He was previously the treasurer of Genentech. Dan will speak on various financing vehicles, including his most recent direct experience raising money through equity lines and a $185 Million royalty deal with TPG-Axon Capital.

This will be a "nuts and bolts" meeting with active audience participation, focused on the pros and cons of the various financing vehicles under discussion. ABFO directors Mike Bates and John Hamilton will moderate the presentations. You should come away with new ideas and contacts to consider for your next trip to the market.

Time is short, so please sign up today.

WHEN: Tuesday, May 20, 2008 6:00 PM - 9:00 PM

WHERE:     Hotel Sofitel
                 223 Twin Dolphin Drive
                 Redwood Shores, CA 94063

COST: $40 - ABFO Member Representatives
$80 - Non-Member Guests

Please RSVP as soon as possible using the links below - barely two weeks left!
You may RSVP and pay for your admission using our ABFO PAYPAL service. You do not
need a PayPal account to use this link.

If you are having difficulty viewing this HTML email, please use this LINK to view it as a webpage FlyingIntoTheSunset